Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flebogamma 5% DIF in Pediatric Primary Immunodeficiency
NCT00634569Phase 4Completed
- Sponsor
- Grifols
- Start
- May 2008
- Primary completion
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of intravenous immunoglobulin G in primary immunodeficiency disease (PID), sponsored by Grifols. Primary endpoint: Serious Bacterial Infections at 12 months. Started May 2008; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT00634569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00634569.